Medplus Health Services: Business Overview & Financial Analysis
MedPlus Health Services is the second-largest pharmacy retail chain in India, founded by Dr. Gangadi Madhukar Reddy. Headquartered in Hyderabad, Telangana, the enterprise operates an integrated omni-channel retail distribution model. MedPlus Health Services supplies prescription medicines, over-the-counter (OTC) pharmaceutical products, personal care items, fast-moving consumer goods (FMCG), private-label formulations, and diagnostic lab testing services across urban, semi-urban, and rural commercial centers in India.
Business Segment & Revenue Breakdown of MedPlus Health Services (Q1 FY27)
MedPlus structures its operational sales across pharmacy retail operations, private-label products, diagnostic testing services, and ancillary channel income.
- Retail Pharmacy Operations – 98.0% of Total Operating Revenue (Rs 1,842.39 crore)
- Diagnostic Services Vertical – 2.0% of Total Operating Revenue (Rs 37.08 crore)
- Total Consolidated Revenue from Operations (Q1 FY27) – Rs 1,879.60 crore (+21.8% YoY)
Pharmacy retail operations serve as the core top-line engine, processing high-volume retail prescription orders. Diagnostic testing labs and collection centers provide ancillary margin realisations.
Product Category Revenue Mix of MedPlus Health Services (Q1 FY27)
MedPlus categorises its retail pharmacy sales across branded pharmaceutical products, private-label medicines, non-pharma FMCG items, and private-label consumer care goods.
- Branded Pharmaceutical Products Share – 63.8% of Total Segment Revenue (Rs 1,198.10 crore)
- Private Label Pharmaceutical Products Share – 10.7% of Total Segment Revenue (Rs 200.90 crore)
- Private Label Non-Pharmaceutical Products Share – 9.3% of Total Segment Revenue (Rs 175.40 crore)
- Branded Non-Pharmaceutical (FMCG) Share – 8.9% of Total Segment Revenue (Rs 166.50 crore)
- Ancillary Channel Income (Membership Fees & Data Income) – 7.3% of Total Segment Revenue (Rs 138.70 crore)
Branded pharmaceuticals contribute nearly two-thirds of store turnover. Private-label medicines and consumer care formulations deliver higher gross margins compared to third-party branded products.
Store Network & Operational Scale of MedPlus Health Services (Q1 FY27)
MedPlus manages a vast retail footprint across company-owned company-operated (COCO) units and franchise outlets.
- Total Active Operational Pharmacy Stores Base – 5,476 operational stores (+146 net new stores added in Q1 FY27)
- Total Franchise Outlets Share – 131 newly onboarded franchisee stores in Q1 FY27
- Total Geographic Coverage Footprint – Presence across 850+ cities and 2,520+ PIN codes
- Total Operational States Base – 10+ states across South, West, and East India
- Average Monthly Store-Level Revenue (Mature Cohort) – ~Rs 12.50 lakh per store
The retail network expanded to 5,476 pharmacies as of June 30, 2026, driven by franchise network scaling. Coverage spans 2,520+ PIN codes across South, West, and East Indian commercial markets.
Diagnostic Network Scale of MedPlus Health Services (Q1 FY27)
MedPlus operates integrated diagnostic reference laboratories, regional testing centers, and patient collection hubs.
- Total Diagnostic Segment Revenue – Rs 37.08 crore (+22.4% YoY)
- Diagnostic Operating EBITDA – Rs 6.59 crore (+59.5% YoY)
- Diagnostic Operating EBITDA Margin – 17.8% (improved 420 bps YoY)
- Operational Testing Infrastructure – Integrated reference labs and collection centers across core metro markets
Diagnostic operations expanded profitability during Q1 FY27, with segment operating EBITDA margins rising to 17.8%. Integrated collection centers utilize existing retail pharmacy footfalls to capture diagnostic test volumes.
Latest Quarterly Financial Performance of MedPlus Health Services (Q1 FY27)
MedPlus recorded top-line revenue expansion alongside margin pressure during the first quarter of FY27.
- Consolidated Revenue from Operations – Rs 1,879.60 crore (+21.8% YoY)
- Consolidated Gross Margin – 24.5% (-160 bps YoY)
- Consolidated Operating EBITDA – Rs 65.12 crore (-10.6% YoY)
- Operating EBITDA Margin – 3.5% (-120 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 33.17 crore (-21.7% YoY)
First-quarter operating revenue rose 21.8% year-on-year to Rs 1,879.60 crore, supported by store network expansion. Consolidated Net Profit After Tax stood at Rs 33.17 crore, impacted by lower private-label sales mix and wage cost inflation.
Consolidated Annual Financial Performance of MedPlus Health Services (FY26)
MedPlus delivered strong full-year turnover expansion and store network growth for full financial year FY26.
- Full Year Consolidated Revenue from Operations – Rs 6,855.00 crore (+20.5% YoY)
- Full Year Operating EBITDA – Rs 350.20 crore (+18.2% YoY)
- Full Year Operating EBITDA Margin – 5.11%
- Full Year Consolidated Net Profit After Tax (PAT) – Rs 185.40 crore (+24.5% YoY)
- Return on Capital Employed (ROCE) – ~12.5%
Full-year operating turnover crossed Rs 6,850 crore in FY26, as consolidated Net Profit After Tax reached Rs 185.40 crore. Performance was driven by new store openings, omni-channel sales dispatches, and supply chain efficiencies.
Balance Sheet Structure & Financial Health Ratios of MedPlus Health Services (Q1 FY27)
MedPlus maintains a disciplined balance sheet structure with low debt gearing and operational working capital lines.
- Net Financial Debt to Equity Ratio – 0.22x
- Total Cash, Bank Balances & Surplus Investments – Rs 420.00 crore
- Total Consolidated Net Worth Base – Rs 1,850.00 crore
- Store Level Operating Cash Flow Conversion – >80.0% of store EBITDA
- Working Capital Inventory Cycle – 52 days
Consolidated net worth stood at Rs 1,850.00 crore as of June 30, 2026, with net debt to equity holding low at 0.22x. Inventory rotation and vendor credit lines support daily store replenishment cycles.
Capital Expenditure & Expansion Roadmap of MedPlus Health Services (FY27–FY28)
MedPlus executes capital allocation outlays to expand franchise store networks, automate distribution centers, and upgrade digital platforms.
- Planned Multi-Year Capex Outlay – Rs 200–250 crore per annum over FY27–FY28
- Annual Net Store Additions Target – 500–600 net new stores annually (Focus on franchise model)
- Warehouse & Automated Logistics Outlay – Expanding central distribution centers in Hyderabad, Chennai, and Bengaluru
- Temporary Capex Abeyance Note – Board temporarily paused a Rs 155 crore non-core expansion project in July 2026 to focus capital on core pharmacy operations
- Funding Method – 100% funded through internal operational cash accruals and liquid reserves
Annual capital expenditure is budgeted at Rs 200–250 crore over FY27–FY28 to add 500–600 stores annually. The company paused non-core capex plans in July 2026 to preserve capital for core pharmacy retail scaling.
Strategic Outlook & Management Commentary of MedPlus Health Services (Q1 FY27 Concall)
Management guidance outlines strategic priorities centered on store network scaling, private-label volume recovery, and operational cost controls.
- Management targets achieving a 20%+ annual top-line revenue CAGR over the FY27–FY29 period.
- Operating EBITDA margins are guided to recover toward the 4.5%–5.5% corridor as new store cohorts mature.
- Private-label product share in pharmacy turnover is targeted to expand back above 15.0%.
- Franchise store onboarding will be prioritized to expand network coverage with minimal capital expenditure.
- Capital allocation strategy will maintain net debt to equity under 0.30x while focusing cash flows on core pharmacy retail.
Management anticipates rising demand for organized healthcare retail and chronic prescription medicines to support top-line growth. Operational focus centers on optimizing store-level cost structures, restoring private-label product mix, and maintaining balance sheet strength.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- MedPlus Health Services Q1 FY27 Investor Presentation & Financial Results (July 22, 2026)
- MedPlus Health Services Stock Exchange Disclosures & BSE Filings (July 21/23, 2026)
- BSE Limited & National Stock Exchange of India (NSE) Corporate Filings for MedPlus Health Services
- Ticker Finology MedPlus Health Services Page
Disclaimer
The information presented above on MedPlus Health Services has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker MedPlus Health Services page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.